FY2029 Earnings Forecast for TVTX Issued By HC Wainwright

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Travere Therapeutics in a research note issued on Wednesday, January 15th. HC Wainwright analyst E. Arce forecasts that the company will earn $4.22 per share for the year. HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($3.92) per share.

Several other brokerages also recently commented on TVTX. Leerink Partners reissued an "outperform" rating and set a $20.00 price objective on shares of Travere Therapeutics in a report on Tuesday, October 8th. Canaccord Genuity Group dropped their target price on shares of Travere Therapeutics from $23.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, September 30th. Barclays increased their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. Bank of America lifted their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. Finally, Wells Fargo & Company raised Travere Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $9.00 to $27.00 in a research note on Monday, October 21st. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $24.00.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX traded up $0.38 during mid-day trading on Thursday, hitting $18.45. The company had a trading volume of 787,133 shares, compared to its average volume of 1,160,856. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $20.33. The stock's 50-day moving average price is $18.23 and its 200-day moving average price is $14.37. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -4.05 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. The business had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. Travere Therapeutics's revenue was up 69.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.17) earnings per share.

Institutional Trading of Travere Therapeutics

Hedge funds have recently modified their holdings of the business. Diversified Trust Co lifted its holdings in shares of Travere Therapeutics by 27.5% during the fourth quarter. Diversified Trust Co now owns 14,701 shares of the company's stock valued at $256,000 after purchasing an additional 3,169 shares during the last quarter. Virtu Financial LLC bought a new position in Travere Therapeutics during the 3rd quarter valued at approximately $301,000. Geode Capital Management LLC raised its stake in Travere Therapeutics by 3.9% during the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company's stock valued at $24,222,000 after buying an additional 64,744 shares during the last quarter. Two Sigma Advisers LP raised its stake in Travere Therapeutics by 30.2% during the third quarter. Two Sigma Advisers LP now owns 720,400 shares of the company's stock valued at $10,078,000 after buying an additional 167,100 shares during the last quarter. Finally, Quarry LP bought a new stake in Travere Therapeutics in the third quarter worth $105,000.

Insider Activity at Travere Therapeutics

In other news, insider Jula Inrig sold 2,066 shares of Travere Therapeutics stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $19.10, for a total transaction of $39,460.60. Following the sale, the insider now owns 59,883 shares of the company's stock, valued at approximately $1,143,765.30. The trade was a 3.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Sandra Calvin sold 12,090 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,927 shares of the company's stock, valued at approximately $1,005,164.10. The trade was a 18.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,596 shares of company stock worth $527,262 in the last 90 days. Company insiders own 4.06% of the company's stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.